Summary
RPG Life sciences is a small player campared to other heavy weights in Indian pharma sector.
They are making progress slowly but surely.
Sirolimus will give them entry into this niche segment of Immunisuppressants which has little competition from the generic players currently.
Having a plant approved by UK MHRA & foreseeable approval from US FDA will help market these product in highly lucrative markets.
Analysis
RPG Life Sciences' Sirolimus is a small step towards a portfolio they are trying to built in the Immunosuppressant space.
Competition in this space is limited & margins are healthy.
With Patents expiry in foreseeable future, this product can add substantial value to the business once its allowed to be marked in developed countries like UK, US , EU etc...
$ 20 - 30 million addition to the bottom line is possible in the next 2 years with sustained marketing effort.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
